US Stock Market News | LaiLi Financial Raises Target Price to $26, Novavax Pharmaceuticals Rises Over 3%

智通財經
2024.10.10 15:01

週四，諾瓦瓦克斯醫藥震盪走高一度上漲逾 5%，截至發稿，漲逾 3%，報 13.08 美元。消息面上，萊利金融分析師 Mayank Mamtani 維持諾瓦瓦克斯醫藥 “買入” 評級，並將目標價從 23 美元上調至 26 美元。

智通財經 APP 獲悉，週四，諾瓦瓦克斯醫藥 (NVAX.US) 震盪走高一度上漲逾 5%，截至發稿，漲逾 3%，報 13.08 美元。消息面上，萊利金融分析師 Mayank Mamtani 維持諾瓦瓦克斯醫藥 “買入” 評級，並將目標價從 23 美元上調至 26 美元。

Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.